Foghorn Therapeutics announced a 45% premarket drop in shares after halting cancer drug development with Eli Lilly and plans to reduce its workforce by 40%.

Observed price moves

• FHTX-1.48%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.